Patients with Cushing disease was randomized to 2 groups. After surgery, the patients were managed with mechanical prevention or mechanical prevention plus anticoagulant drugs(LMWH followed by rivaroxaban), VTE was observed 24h, 5day, 4weeks and 12weeks after surgery.Bleeding events were also recorded.
Eligibility
Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria:
* Cushing\'s disease diagnosed and treated with transsphenoid surgery at study centers
Exclusion Criteria:
1. History of VTE before surgery or within 24 hours post-surgery
2. Acute bacterial endocarditis
3. Major bleeding events
4. Thrombocytopenia
5. Active gastrointestinal ulcers
6. History of stroke
7. High risk of bleeding due to clotting abnormalities
8. Participation in other clinical trials within the last three months
9. Contraindications to rivaroxaban (e.g., renal dysfunction with eGFR \< 50 mL/min)
10. Presence of other malignant diseases
11. Severe mental or neurological disorders
12. Presence of intracranial vascular abnormalities
13. Contraindications to mechanical prophylactic anticoagulation
14. Pregnancy
15. Any other condition that researchers deem inappropriate for study participation.
Primary outcome measure(s)
VTE incidence rate — 12 weeks DVT and PE incidence in 12 weeks after surgery
Trial sites (7)
Facility
City
Region
Status
The First Affiliated Hospital of Fujian Medical University
Fuzhou
Fujian
The First Affiliated Hospital of Sun Yat sen University
Guangzhou
Guangdong
Tongji Hospital
Wuhan
Hubei
Huashan Hospital
Shanghai
Shanghai Municipality
China West Hospital
Chengdu
Sichuan
People's Hopital of Xinjiang Uygur Autonomous Region
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.